Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis ?

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

Sixty days of ciprofloxacin administration at 500 mg every 12 h is currently recommended for the prophylaxis of inhalational exposure to Bacillus anthracis. We examined Bacillus anthracis (Delta-Sterne strain) in our hollow-fiber infection model. We measured the ciprofloxacin concentrations achieved and the number of organisms present before heat shock (total population) and after heat shock (spore population). We fit a mathematical model to these data. Monte Carlo simulation with differing initial spore burdens (3, 5, and 6.9 log(10) CFU/ml) demonstrated that 35 days of this regimen would completely clear the spore burden in 95% of patients. Durations of 110 days did not achieve 99.9% eradication, irrespective of initial burden, because of between-patient variance in drug pharmacokinetics. Given the absence of person-to-person transmission for Bacillus anthracis, adverse drug effects with long-term ciprofloxacin administration, and the possibility of engendering resistance in bodily flora, shorter prophylaxis duration should be given consideration, along with careful monitoring of all exposed individuals.

Knowledge Graph

Similar Paper

Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis ?
Antimicrobial Agents and Chemotherapy 2008.0
Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax
Antimicrobial Agents and Chemotherapy 2008.0
Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model
Antimicrobial Agents and Chemotherapy 2007.0
Impact of Spore Biology on the Rate of Kill and Suppression of Resistance in Bacillus anthracis
Antimicrobial Agents and Chemotherapy 2009.0
Efficacy of Daptomycin against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation
Antimicrobial Agents and Chemotherapy 2010.0
Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis
Antimicrobial Agents and Chemotherapy 2008.0
Activity of Dalbavancin against Bacillus anthracis In Vitro and in a Mouse Inhalation Anthrax Model
Antimicrobial Agents and Chemotherapy 2010.0
A Rapid Antimicrobial Susceptibility Test for Bacillus anthracis
Antimicrobial Agents and Chemotherapy 2010.0
Pharmacokinetic-Pharmacodynamic Assessment of Faropenem in a Lethal Murine Bacillus anthracis Inhalation Postexposure Prophylaxis Model
Antimicrobial Agents and Chemotherapy 2010.0
Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin
Antimicrobial Agents and Chemotherapy 2007.0